Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05191706
PHASE4

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Sponsor: EyePoint Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Official title: A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Key Details

Gender

All

Age Range

Any - 3 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2022-01-04

Completion Date

2026-02

Last Updated

2025-04-03

Healthy Volunteers

No

Conditions

Interventions

DRUG

Dexamethasone

single anterior chamber injection

DRUG

Prednisolone Acetate Ophthalmic

topical administration four times a day for 28 days, followed by treatment taper

Locations (9)

EyePoint Investigational Site

Huntington Beach, California, United States

EyePoint Investigational Site

Palo Alto, California, United States

EyePoint Investigative Site

Boston, Massachusetts, United States

EyePoint Investigational Site

Jackson, Mississippi, United States

EyePoint Investigational Site

Omaha, Nebraska, United States

EyePoint Investigational Site

Buffalo, New York, United States

EyePoint Investigative Site

New York, New York, United States

EyePoint Investigational Site

Rochester, New York, United States

EyePoint Investigational Site

Charleston, South Carolina, United States